A phase-II randomized trial (N=76) of pembrolizumab (PD-1 inhibitor) after stereotactic body radiotherapy (SBRT) (n=36) vs. pembrolizumab alone (n=40) in advanced NSCLC concluded that radioimmunotherapy was associated with improvement in overall response rate at 12 weeks [16]. This evidence concerns the gene PDCD1 and non-small cell lung carcinoma.